Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
NCT03932318 · Actinium Pharmaceuticals · PHASE1/PHASE2 · withdrawn · last registry update 2023-07-20 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “study postponed” | Open Targets' class: invalid reason | Registry record, Actinium Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT06073730)
- 2023-09-18Results posted on the registry: Takeda, Pevonedistat + Venetoclax (NCT04266795)
- 2023-07-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Venetoclax Oral Tablet + Daunorubicin (NCT05939180)
- 2023-01-27Results posted on the registry: AbbVie, Azacitidine + Venetoclax (NCT02993523)
- 2022-12-16Phase 3 first posted: The First Affiliated Hospital of Soochow University, Azacitidine Combined With Venetoclax and ATRA group (NCT05654194)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision